131060-08-7

Basic information

• Product Name: 4-(chloropropyl)-1-(2-quinolyl)piperazine
• Synonyms: 4-(chloropropyl)-1-(2-quinolyl)piperazine;2-[4-(3-Chloropropyl)-1-piperazinyl]quinoline;AAL-13
• CAS NO: 131060-08-7
• Molecular Formula: C16H20 Cl N3
• Molecular Weight: 289.8
• Mol File: 131060-08-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 453.9°Cat760mmHg
• Flash Point: 228.3°C
• Appearance: /
• Density: 1.18g/cm³
• Vapor Pressure: 1.51E-07mmHg at 25°C
• Refractive Index: 1.611
• CAS DataBase Reference: 4-(chloropropyl)-1-(2-quinolyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(chloropropyl)-1-(2-quinolyl)piperazine(131060-08-7)
• EPA Substance Registry System: 4-(chloropropyl)-1-(2-quinolyl)piperazine(131060-08-7)

Safety Data

• Hazardous Substances Data: 131060-08-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C16H20ClN3/c1-2-15(17)19-9-11-20(12-10-19)16-8-7-13-5-3-4-6-14(13)18-16/h3-8,15H,2,9-12H2,1H3

Upstream product

• 612-62-4 2-Chloroquinoline 
• 4774-24-7 2-(piperazin-1-yl)quinoline 
• 109-70-6 1.3-chlorobromopropane 

Downstream Products

• 139477-46-6 2-<3-<4-<2-(quinolyl)>-1-piperazinyl>propyl>-1,2,4-triazolo<4,3-a>pyridin-3(2H)-one 

Relevant articles and documents

New hybrids of quipazine and trazodone as selective inhibitors of uptake of 5-hydroxytryptamine

Two new congeners, 4-(chloropropyl)-1-(2-quinolyl)piperazine- and 2-[3-[4- [2-(quinolyl)]-1-piperazinyl]propyl]-1,2,4-triazolo]4,3-a]pyridin-3(2H)-one, of trazodone were synthesized and found to be potent and selective inhibitors of synaptosomal uptake of 5-hydroxytryptamine [5-HT, serotonin; IC50 = norepinephrine > 5 μM, 5-HT = 210-890 nM], with minimal effects in antagonizing (-)-apomorphine-induced climbing behavior and suppression of spontaneous locomotor activity in mice (ED50 > 50 mg/kg). The two compounds behaved like atypical antidepressants, since they weakly antagonized reserpine-induced hypothermia. The acute toxicity studies have shown that these compounds were less lethal when compared with imipramine or quipazine. Furthermore, chronic treatments (20 mg/kg, daily for 10 and 21 days) significantly decreased the isoprenaline-induced increase in cyclic AMP in the rat brain cortex, suggesting desensitization of β-adrenoceptors. These findings point to the effects of these compounds as potential antidepressants dealing with specific serotonergic mechanisms.

PYRIMIDINE DERIVATIVE

This invention provides pyrimidine derivatives represented by a formula, in the formula, ring A stands for carbocyclic group or heterocyclic group, X 1 stands for hydrogen, lower alkyl, amino, etc., X 2 stands for hydrogen or lower alkyl, Y stands for a direct bond or sulfur or nitrogen, n stands for an integer of 0 - 4, and Ar stands for a group of the following formula, or a salt thereof, which concurrently exhibit 5-HT 1A agonistic activity and 5-HT 3 antagonistic activity and are useful for therapy and treatments of diseases such as IBS. The invention furthermore provides a therapeutic method of IBS, characterized by having 5-HT 1A agonistic activity and 5-HT 3 antagonistic activity work simultaneously and cooperatively in vivo, which comprises either administering 5-HT 3 antagonistic agent which concurrently exhibits 5-HT 1A agonistic activity, or administering 5-HT 1A agonistic agent and 5-HT 3 antagonistic agent simultaneously, in sequence or at an interval.